NO20002691L - IFNAR2/IFN kompleks - Google Patents
IFNAR2/IFN kompleksInfo
- Publication number
- NO20002691L NO20002691L NO20002691A NO20002691A NO20002691L NO 20002691 L NO20002691 L NO 20002691L NO 20002691 A NO20002691 A NO 20002691A NO 20002691 A NO20002691 A NO 20002691A NO 20002691 L NO20002691 L NO 20002691L
- Authority
- NO
- Norway
- Prior art keywords
- ifn
- complex
- ifnar
- interferon
- peptide
- Prior art date
Links
- 101000852865 Homo sapiens Interferon alpha/beta receptor 2 Proteins 0.000 title 1
- 102100036718 Interferon alpha/beta receptor 2 Human genes 0.000 title 1
- 102000014150 Interferons Human genes 0.000 abstract 10
- 108010050904 Interferons Proteins 0.000 abstract 10
- 229940079322 interferon Drugs 0.000 abstract 10
- 101000852870 Homo sapiens Interferon alpha/beta receptor 1 Proteins 0.000 abstract 3
- 102100036714 Interferon alpha/beta receptor 1 Human genes 0.000 abstract 3
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000002227 Interferon Type I Human genes 0.000 abstract 1
- 108010014726 Interferon Type I Proteins 0.000 abstract 1
- 108020004511 Recombinant DNA Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6829597P | 1997-12-19 | 1997-12-19 | |
| PCT/US1998/026926 WO1999032141A1 (en) | 1997-12-19 | 1998-12-18 | Ifnar2/ifn complex |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20002691D0 NO20002691D0 (no) | 2000-05-25 |
| NO20002691L true NO20002691L (no) | 2000-08-18 |
Family
ID=22081665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20002691A NO20002691L (no) | 1997-12-19 | 2000-05-25 | IFNAR2/IFN kompleks |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6372207B1 (es) |
| EP (1) | EP1037658B1 (es) |
| JP (1) | JP4601163B2 (es) |
| KR (1) | KR100593981B1 (es) |
| CN (1) | CN1241638C (es) |
| AR (1) | AR020315A1 (es) |
| AT (1) | ATE218362T1 (es) |
| AU (1) | AU755078B2 (es) |
| BG (1) | BG64920B1 (es) |
| BR (1) | BR9813753A (es) |
| CA (1) | CA2311648C (es) |
| DE (1) | DE69805844T2 (es) |
| DK (1) | DK1037658T3 (es) |
| EA (1) | EA003635B1 (es) |
| EE (1) | EE200000355A (es) |
| ES (1) | ES2174530T3 (es) |
| HU (1) | HUP0100456A3 (es) |
| IL (2) | IL136855A0 (es) |
| NO (1) | NO20002691L (es) |
| NZ (1) | NZ504771A (es) |
| PL (1) | PL197568B1 (es) |
| PT (1) | PT1037658E (es) |
| SK (1) | SK9222000A3 (es) |
| TR (1) | TR200001961T2 (es) |
| UA (1) | UA74132C2 (es) |
| WO (1) | WO1999032141A1 (es) |
| ZA (1) | ZA9811634B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL122818A0 (en) * | 1997-07-10 | 1998-08-16 | Yeda Res & Dev | Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof |
| AUPP670698A0 (en) * | 1998-10-23 | 1998-11-19 | Monash University | A method of regulation |
| US7138379B2 (en) * | 2000-07-26 | 2006-11-21 | Schering Aktiengesellschaft | Use of the interferon receptor 2c polypeptide chain to enhance the anti-growth effects of type I interferons |
| IL147414A0 (en) | 2001-12-31 | 2002-08-14 | Yeda Res & Dev | Ifnar2 mutants, their production and use |
| US20040175359A1 (en) * | 2002-11-12 | 2004-09-09 | Desjarlais John Rudolph | Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity |
| JP4850514B2 (ja) * | 2003-08-25 | 2012-01-11 | 東レ株式会社 | インターフェロンβ複合体 |
| CN100400664C (zh) * | 2005-09-06 | 2008-07-09 | 中国人民解放军第四军医大学 | 肿瘤血管导向肽与人干扰素α-2b的融合蛋白的制备方法 |
| WO2008130382A2 (en) | 2006-10-31 | 2008-10-30 | East Carolina University | Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders |
| GB0715383D0 (en) * | 2007-08-08 | 2007-09-19 | Asterion Ltd | Interferon |
| GB0815216D0 (en) * | 2008-08-21 | 2008-09-24 | Asterion Ltd | Interleukin |
| EP3348275A3 (en) | 2009-03-31 | 2018-10-24 | East Carolina University | Cytokines and neuroantigens for treatment of immune disorders |
| KR101293363B1 (ko) * | 2011-02-28 | 2013-08-05 | 성균관대학교산학협력단 | 인터페론 수용체 유전자를 포함하는 조류독감 예방용 조성물 |
| WO2014151422A1 (en) * | 2013-03-15 | 2014-09-25 | Janssen Biotech, Inc. | Interferon alpha and omega antibody antagonists |
| LT6164B (lt) | 2013-10-15 | 2015-06-25 | Uab Biotechnologinės Farmacijos Centras "Biotechpharma" | Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas |
| AU2017290389B2 (en) | 2016-07-01 | 2024-09-26 | Resolve Therapeutics, Llc | Optimized binuclease fusions and methods |
| CA3067539A1 (en) * | 2017-06-20 | 2018-12-27 | The Board Of Regents Of The University Of Texas System | Interferon prodrug for the treatment of cancer |
| BR112020003670A2 (pt) | 2017-08-22 | 2020-09-01 | Sanabio, Llc | receptores de interferon solúveis e usos dos mesmos |
| CN112646783B (zh) * | 2020-12-30 | 2023-12-01 | 广州医科大学附属市八医院 | 表达基因、经基因修饰的受精卵的构建方法和小鼠模型的构建方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5821078A (en) | 1992-09-03 | 1998-10-13 | Yeda Research And Development Co. Ltd. | Nucleic acid encoding interferon-α/β binding protein |
| IL106591A (en) | 1992-09-03 | 2008-03-20 | Yeda Res & Dev | Interferon alpha/beta binding protein, its preparation and pharmaceutical compositions containing it |
| IL107378A (en) * | 1993-10-24 | 2005-05-17 | Yeda Res & Dev | SOLUBLE INTERFERON alpha-RECEPTOR, ITS PREPARATION AND USE |
-
1998
- 1998-12-18 AR ARP980106515A patent/AR020315A1/es active IP Right Grant
- 1998-12-18 HU HU0100456A patent/HUP0100456A3/hu unknown
- 1998-12-18 KR KR1020007006160A patent/KR100593981B1/ko not_active Expired - Fee Related
- 1998-12-18 SK SK922-2000A patent/SK9222000A3/sk unknown
- 1998-12-18 DE DE69805844T patent/DE69805844T2/de not_active Expired - Lifetime
- 1998-12-18 CA CA2311648A patent/CA2311648C/en not_active Expired - Fee Related
- 1998-12-18 NZ NZ504771A patent/NZ504771A/xx unknown
- 1998-12-18 UA UA2000074350A patent/UA74132C2/uk unknown
- 1998-12-18 ZA ZA9811634A patent/ZA9811634B/xx unknown
- 1998-12-18 PT PT98964071T patent/PT1037658E/pt unknown
- 1998-12-18 EE EEP200000355A patent/EE200000355A/xx unknown
- 1998-12-18 WO PCT/US1998/026926 patent/WO1999032141A1/en not_active Ceased
- 1998-12-18 CN CNB988123924A patent/CN1241638C/zh not_active Expired - Fee Related
- 1998-12-18 US US09/215,212 patent/US6372207B1/en not_active Expired - Lifetime
- 1998-12-18 EA EA200000685A patent/EA003635B1/ru not_active IP Right Cessation
- 1998-12-18 TR TR2000/01961T patent/TR200001961T2/xx unknown
- 1998-12-18 IL IL13685598A patent/IL136855A0/xx active IP Right Grant
- 1998-12-18 BR BR9813753-0A patent/BR9813753A/pt not_active Application Discontinuation
- 1998-12-18 JP JP2000525131A patent/JP4601163B2/ja not_active Expired - Fee Related
- 1998-12-18 PL PL341423A patent/PL197568B1/pl not_active IP Right Cessation
- 1998-12-18 EP EP98964071A patent/EP1037658B1/en not_active Expired - Lifetime
- 1998-12-18 AT AT98964071T patent/ATE218362T1/de not_active IP Right Cessation
- 1998-12-18 ES ES98964071T patent/ES2174530T3/es not_active Expired - Lifetime
- 1998-12-18 AU AU19269/99A patent/AU755078B2/en not_active Ceased
- 1998-12-18 DK DK98964071T patent/DK1037658T3/da active
-
2000
- 2000-05-25 NO NO20002691A patent/NO20002691L/no not_active Application Discontinuation
- 2000-06-15 BG BG104539A patent/BG64920B1/bg unknown
- 2000-06-18 IL IL136855A patent/IL136855A/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20002691L (no) | IFNAR2/IFN kompleks | |
| Lortat-Jacob et al. | Interferon-γ binds to heparan sulfate by a cluster of amino acids located in the C-terminal part of the molecule | |
| Pollaro et al. | Strategies to prolong the plasma residence time of peptide drugs | |
| ES2307718T3 (es) | Peptido 2 similar al flucagon (glp-2) de duracion prolongada para el tratamiento de enfermedades y trastornos gastrointestinales. | |
| DK1105409T3 (da) | Beskyttelse af endogene terapeutiske peptider fra peptidaseaktivitet ved konjugering med blodkomponenter | |
| EP1504037A4 (en) | FERRITINFUSION PROTEINS FOR USE IN VACCINES AND OTHER APPLICATIONS | |
| JP2006514607A5 (es) | ||
| ATE216225T1 (de) | Diagnostische verfahren und pharmazeutische zusammensetzungen auf der basis von notch- proteinen und nukleinsäuren | |
| DK0661989T3 (da) | Proteinsammensætninger med vedvarende frigivelse | |
| PT1264840E (pt) | Péptidos de fusão inibidores, de acção prolongada, de infecção viral | |
| ATE348883T1 (de) | Zusammensetzungen und verfahren mit analogen von g-csf | |
| DE60125751D1 (de) | Zusammensetzungen und verfahren zur behinderung der vervielfältigung von hiv-1 | |
| JP2001526242A5 (es) | ||
| DE69328035D1 (de) | Polypeptide, von endonexin 2 stammend, mit hepatitis b virus rezeptor aktivität und deren verwendungen in diagnotischen und pharmazeutischen zusammensetzungen | |
| ATE258061T1 (de) | Tri-, tetra-, penta- und polypeptide und ihre therapeutische verwendung als antidepressiva | |
| DE68921674D1 (de) | Peptide, deren Verwendung als Immuno-Suppressanten und Verfahren zu deren Herstellung. | |
| JPH01131197A (ja) | Ａｎｆ活性を有するペプチド類 | |
| DE69712182D1 (de) | Peptide und ihre verwendung in der therapie von krankheiten des zöliakie-formenkreises | |
| WO2002036628A3 (en) | New multimeric interferon beta polypeptides | |
| DE69534738D1 (de) | Leukocyten-aktivierender Faktor | |
| NZ513915A (en) | Chimeric proteins comprising 6 contiguous amino acids that bind to the GIT fused to a second protein, which may be a drug | |
| ES2051152B1 (es) | Procedimiento de sistesis de peptidos con capacidad de detectar anticuerpos anti-virus de la hepatitis c (vhc) en suero de individuos afectados. | |
| ATE347899T1 (de) | Interferon nachahmende peptide und rekombinante proteine | |
| JP2001278895A (ja) | インターフェロン作用増強性ペプチド及び該ペプチドとインターフェロンとを含有するインターフェロン作用増強組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CREP | Change of representative |
Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS |
|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |